Patients Switched to High-Dose Aflibercept Saw Retina Gains
A clinical study shows that patients with nAMD treated with 8 mg aflibercept achieved improved retinal stability.
Updated on Sept. 29, 2026 in Biotech
Live Poll
Does reading about real-world treatment outcomes increase your trust in new medical therapies?
Researchers analyzed 30 patients who transitioned from faricimab to 8 mg aflibercept for neovascular age-related macular degeneration (nAMD). The study found reduced retinal thickness and pigment epithelial detachment height after three monthly injections.
Why it matters
This research provides clinical insights for managing patients with nAMD who have already undergone multiple anti-VEGF therapies. Understanding the response to dosage adjustments is critical for refining long-term treatment strategies in retinal care.
Participants with a mean baseline central retinal thickness of 308.3 µm showed improvement after receiving three monthly 8 mg intravitreal injections. This group had significant prior exposure, averaging 22.7 total anti-VEGF treatments.
The players
nAMD Patients
The study cohort consisted of 30 individuals with a mean age of 79.8 years who had undergone extensive prior anti-VEGF therapy.
The details
The study utilized intravitreal injections — medication delivered directly into the vitreous fluid of the eye — to administer 8 mg aflibercept. Researchers measured best-corrected visual acuity and central retinal thickness to assess anatomical changes. Among the 30 patients, 80% exhibited pigment epithelial detachment — a separation of the retina's outer layer — at baseline, which was assessed following the switch from faricimab.
Timeline
Patients received a mean of 22.7 anti-VEGF injections before the study.
Initial clinical markers were measured at the study baseline.
The first maintenance injection was scheduled 12 weeks after the loading phase.
A second maintenance injection was planned at 12 or 16 weeks during the maintenance phase.
The Tech Race
This research follows a pattern of refining dosage regimens within established anti-VEGF clinical protocols for macular degeneration. It builds upon existing data regarding how retinal structures respond to transitioning between therapeutic agents.
This finding informs treatment options for patients currently undergoing anti-VEGF therapy for macular degeneration. The transition protocol is specific to those with prior treatment history and requires ongoing oversight by a retinal specialist.
The takeaway
The study demonstrates the potential for structural retinal improvement in patients transitioning to 8 mg aflibercept after previous treatments. Watch for future findings regarding the 12-week and 16-week maintenance phase results to confirm the long-term efficacy of this dosage schedule.
What happens next
Clinicians and researchers will monitor patient outcomes during the upcoming 12- and 16-week maintenance intervals to determine the long-term durability of the observed retinal improvements.
Further reading
Explore deeper into advancements in Biotech to understand current trends in ophthalmology research.
Source note: This article includes information reported by Nature.
Live Poll
Does reading about real-world treatment outcomes increase your trust in new medical therapies?
